Deborah Berg

6.2k total citations · 2 hit papers
66 papers, 3.6k citations indexed

About

Deborah Berg is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Deborah Berg has authored 66 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Molecular Biology, 47 papers in Hematology and 25 papers in Oncology. Recurrent topics in Deborah Berg's work include Multiple Myeloma Research and Treatments (42 papers), Protein Degradation and Inhibitors (28 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Deborah Berg is often cited by papers focused on Multiple Myeloma Research and Treatments (42 papers), Protein Degradation and Inhibitors (28 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Deborah Berg collaborates with scholars based in United States, Canada and Italy. Deborah Berg's co-authors include Charles A. Schiffer, Robert J. Mayer, Philip Schulman, Joseph O. Moore, Bayard L. Powell, George Omura, O. Ross McIntyre, E Frei, Roger B. Davis and Neeraj Gupta and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Deborah Berg

64 papers receiving 3.5k citations

Hit Papers

Intensive Postremission Chemotherapy in Adults with Acute... 1994 2026 2004 2015 1994 1998 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
    1994 1.0k citations Robert J. Mayer, Roger B. Davis et al. New England Journal of Medicine profile →
  2. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    1998 508 citations Deborah Berg, Charles A. Schiffer et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deborah Berg United States 24 2.9k 2.0k 1.1k 819 584 66 3.6k
Claude Gardin France 35 3.2k 1.1× 1.9k 1.0× 750 0.7× 800 1.0× 1.1k 1.9× 123 4.3k
Jonathan Kell United Kingdom 20 1.9k 0.7× 1.1k 0.6× 574 0.5× 683 0.8× 392 0.7× 57 2.5k
Mar Tormo Spain 32 2.1k 0.7× 1.3k 0.7× 646 0.6× 1.0k 1.3× 506 0.9× 106 3.1k
Åsa Rangert Derolf Sweden 19 2.2k 0.8× 1.2k 0.6× 525 0.5× 613 0.7× 1.2k 2.0× 42 2.8k
Eytan M. Stein United States 28 2.3k 0.8× 2.0k 1.0× 617 0.5× 511 0.6× 636 1.1× 203 3.4k
Hussain I. Saba United States 20 1.8k 0.6× 1.6k 0.8× 692 0.6× 384 0.5× 595 1.0× 45 3.2k
Ellin Berman United States 31 2.2k 0.8× 1.2k 0.6× 1.2k 1.1× 871 1.1× 992 1.7× 99 3.8k
Bart L. Scott United States 35 3.8k 1.3× 1.0k 0.5× 509 0.4× 1.0k 1.3× 1.6k 2.7× 169 4.3k
Ralph Wäsch Germany 31 2.1k 0.7× 1.6k 0.8× 1.2k 1.1× 324 0.4× 333 0.6× 172 3.3k
Agnieszka Wierzbowska Poland 22 1.5k 0.5× 1.1k 0.6× 483 0.4× 435 0.5× 461 0.8× 108 2.3k

Countries citing papers authored by Deborah Berg

Since Specialization
Citations

This map shows the geographic impact of Deborah Berg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Berg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Berg more than expected).

Fields of papers citing papers by Deborah Berg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Berg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Berg. The network helps show where Deborah Berg may publish in the future.

Co-authorship network of co-authors of Deborah Berg

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Berg. A scholar is included among the top collaborators of Deborah Berg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Berg. Deborah Berg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Assouline, Sarit, Amitkumar Mehta, Walter Hanel, et al.. (2025). Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 25(11). 788–799.e11. 1 indexed citations
2.
Patel, Krina K., Meera Mohan, Sundar Jagannath, et al.. (2024). Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma. PubMed. 1(4). 100043–100043.
3.
4.
Iida, Shinsuke, Tohru Izumi, Takuya Komeno, et al.. (2021). A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma. International Journal of Clinical Oncology. 27(1). 224–233. 5 indexed citations
5.
Dispenzieri, Angela, Ashutosh Wechalekar, Stefan Schönland, et al.. (2019). Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood. 134(Supplement_1). 139–139. 32 indexed citations
6.
Kumar, Shaji, Jesús G. Berdeja, Rubén Niesvizky, et al.. (2019). Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 33(7). 1736–1746. 38 indexed citations
7.
8.
Garderet, Laurent, Jacob P. Laubach, Anne‐Marie Stoppa, et al.. (2018). Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. Leukemia. 32(9). 2032–2036. 6 indexed citations
9.
Sanchorawala, Vaishali, Giovanni Palladini, Vishal Kukreti, et al.. (2017). A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 130(5). 597–605. 101 indexed citations
10.
Gupta, Neeraj, Paul M. Diderichsen, Michael J. Hanley, et al.. (2017). Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. Clinical Pharmacokinetics. 56(11). 1355–1368. 39 indexed citations
11.
Richardson, Paul, Shaji Kumar, Jacob P. Laubach, et al.. (2017). New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib. Journal of Blood Medicine. Volume 8. 107–121. 15 indexed citations
12.
Lin, Huamao Mark, Xīn Gào, Catherine E. Cooke, et al.. (2017). Disease burden of systemic light-chain amyloidosis: a systematic literature review. Current Medical Research and Opinion. 33(6). 1017–1031. 25 indexed citations
13.
Smith, David C., Thea Kalebic, Jeffrey R. Infante, et al.. (2015). Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Investigational New Drugs. 33(3). 652–663. 35 indexed citations
14.
15.
Berg, Deborah. (2006). Capecitabine: A New Adjuvant Option for Colorectal Cancer. Clinical journal of oncology nursing. 10(4). 479–486. 2 indexed citations
16.
Berg, Deborah. (2003). Oxaliplatin: A Novel Platinum Analog With Activity in Colorectal Cancer. Oncology nursing forum. 30(6). 957–966. 4 indexed citations
17.
Ryan, David P., T. J. Lynch, Michael L. Grossbard, et al.. (2000). A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors. Cancer. 88(1). 180–185. 5 indexed citations
18.
Stone, Richard M., Deborah Berg, Stephen L. George, et al.. (1995). Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia. New England Journal of Medicine. 332(25). 1671–1677. 335 indexed citations
19.
Mayer, Robert J., Roger B. Davis, Charles A. Schiffer, et al.. (1994). Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia. New England Journal of Medicine. 331(14). 896–903. 1027 indexed citations breakdown →
20.
Rubin, Eric H., J. W. Andersen, Deborah Berg, et al.. (1992). Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.. Journal of Clinical Oncology. 10(6). 948–953. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claude Gardin Breakdown of academic impact, for papers by Jonathan Kell Breakdown of academic impact, for papers by Mar Tormo Breakdown of academic impact, for papers by Åsa Rangert Derolf Breakdown of academic impact, for papers by Eytan M. Stein Breakdown of academic impact, for papers by Hussain I. Saba Breakdown of academic impact, for papers by Ellin Berman Breakdown of academic impact, for papers by Bart L. Scott Breakdown of academic impact, for papers by Ralph Wäsch Breakdown of academic impact, for papers by Agnieszka Wierzbowska
Rankless by CCL
2026